-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OyKBCtpngxSRbTetdml852b/VdoNTtgaiRituDlx7TYyqnUcuM9GO1HYBIK5z0Kc w3eFMabwhEd4PSsvsUTh0A== 0001169232-03-005806.txt : 20030925 0001169232-03-005806.hdr.sgml : 20030925 20030925161708 ACCESSION NUMBER: 0001169232-03-005806 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DISCOVERY LABORATORIES INC /DE/ CENTRAL INDEX KEY: 0000946486 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171943 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-35206 FILM NUMBER: 03910205 BUSINESS ADDRESS: STREET 1: 350 MAIN STREET SUITE 307 CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2152404699 MAIL ADDRESS: STREET 1: 350 MAIN STREET SUITE 307 CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961121 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN INC DATE OF NAME CHANGE: 19950609 424B3 1 d56999_424b3.txt FORM 424B3 Filed pursuant to Rule 424(b)(3) relating to Registration Statement No. 333-35206 DISCOVERY LABORATORIES, INC. SUPPLEMENT DATED SEPTEMBER 25, 2003 TO PROSPECTUS DATED APRIL 20, 2000 This Supplement should be read in conjunction with the Prospectus dated April 20, 2000, contained in Registration Statement No. 333-35206 of Discovery Laboratories, Inc., as amended and supplemented by the Registration Statement and Prospectus on Form S-3/A filed by us on June 1, 2000, and including the exhibits and the documents incorporated by reference thereto. The selling stockholder table contained in such Prospectus is amended by deleting the references to Omicron Partners L.P., and adding the entity, Omicron Master Trust as listed in the table below as a new selling stockholder (the "Selling Stockholder"). In connection with a reorganization of Omicron Partners, L.P., Omicron Partners has transferred all of the securities registered for resale pursuant to the above-referenced Registration Statement and Prospectus to the Selling Stockholder. Our common stock, par value $.001 per share, is listed on the Nasdaq SmallCap Market under the symbol "DSCO". On September 12, 2003, the closing sale price for the common stock, as reported on the Nasdaq SmallCap Market, was $8.08. We advise you to obtain a current market quotation for the common stock. Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. The Selling Stockholder may offer and sell a total of 64,615 shares of common stock under the Prospectus. The shares being offered under the Prospectus were acquired by the Selling Stockholder upon the transfer of securities issued to Omicron Partners in connection with a private placement consummated by us in March 2000. In connection with such Private Placement, we agreed to register these shares for Omicron Partners and their assignees under the Securities Act of 1933. The following table sets forth, to the best of our knowledge, based on information provided to us by the Selling Stockholder: - --the number of shares of common stock owned by the Selling Stockholder; and - --the number of shares being offered by the Selling Stockholder under the Prospectus. All information with respect to share ownership has been provided by the Selling Stockholder as of a recent date. Because the Selling Stockholder may have sold, transferred or otherwise disposed of all or a portion of the shares of common stock owned by the Selling Stockholder since the date on which it provided us with the information regarding its share ownership in transactions exempt from the registration requirements of the Securities Act of 1933, no estimate can be given as to the number of shares of common stock that will be held by the Selling Stockholder after the offering. The information appearing in the following table supplements or supersedes in part the information in the table under the heading "Selling Stockholder" in the Prospectus and was provided by or on behalf of the entity named below, as of September 12, 2003. SELLING STOCKHOLDERS
Number of Shares of common Number of Number of stock, not Shares Total Number Shares to be Number of Percentage including represented of Shares of Percentage Offered for Shares to to be Warrants, by Warrants common stock Beneficially the Account be Owned Beneficially Beneficially Beneficially Beneficially Owned Before of Selling after this Owned After Name Owned Owned Owned + Offering Stockholders Offering this Offering - ---------------------------------------------------------------------------------------------------------------------------------- Omicron Master Trust 53,846 10,769 64,615 * 64,615 0
- ---------- * Less than 1% + The information contained in this table reflects "beneficial" ownership of common stock within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934. On September 12, 2003, we had 42,170,539 (not including treasury shares) shares of common stock outstanding. Beneficial ownership information reflected in the table includes shares of common stock issuable upon the exercise of outstanding warrants. Please keep this supplement with your Prospectus. 2
-----END PRIVACY-ENHANCED MESSAGE-----